Stepping Beyond the Status Quo in Heart Failure: The Revolutionary Role of SGLT2 Inhibition
This Grand Rounds initiative is targeted to cardiologists, endocrinologists, primary care physicians, pharmacists, nurses, nurse practitioners, and physician assistants. Designed to foster meaningful interprofessional and interdisciplinary collaboration, this accredited activity will explore the evolution of SGLT2 inhibition in the era of cardiovascular outcomes trials (CVOTs), as well as evaluate foundational mechanisms linking type 2 diabetes (T2D) to heart failure (HF). Expert faculty will also examine new and emerging CVOT data for SGLT2 inhibitors, including recent approvals and guideline recommendations, and offer insights into how these agents are shifting the HF treatment paradigm and broadening horizons for both diabetic and nondiabetic patients. To reinforce these teaching points within the context of a collaborative approach, attendees will be engaged in a case-based discussion focused on key characteristics of an effective, integrated approach to HF management.
Cardiologists, endocrinologists, primary care physicians, pharmacists, nurses, nurse practitioners, and physician assistants, focused on the integration of new and emerging CVOT data into clinical practice, with an emphasis on collaborative management of heart failure.
At the conclusion of this activity, participants will be able to:
- Explore the evolution of SGLT2 inhibition in the CVOT era and evaluate mechanisms linking T2D and heart failure (HF).
- Appraise new and emerging CVOT data for antihyperglycemic agents and compare outcomes data across the type 2 diabetes (T2D) therapeutic classes.
- Examine recently-reported CVOT data for SGLT2 inhibitors, and discuss ways that these agents are shifting the HF treatment paradigm and broadening horizons for both diabetic and nondiabetic patients.
- Using a case-based format, recognize opportunities for cardiologists to collaborate with endocrinologists, primary care providers, and other members of the healthcare team, and identify key characteristics of an integrated approach to HF management.
Jarett Berry, MD, MS, FAHA
Associate Professor of Medicine and Clinical Sciences
Dedman Family Scholar in Clinical Care
Division of Cardiology
University of Texas Southwestern Medical Center
Dr. Berry is a Dedman Family Scholar in Clinical Care and an Associate Professor of Medicine and an Associate Professor of Clinical Sciences at UT Southwestern in Dallas, TX. He completed his Medical Degree and Internal Medicine residency at UT Southwestern, and his Clinical Cardiology and research training at Northwestern University in Chicago, IL.
Dr. Berry’s clinical interests include both preventive cardiology and general cardiology where he serves as the Director of Cardiac Rehabilitation and an attending physician in the coronary care unit at Parkland Hospital. He has a nationally recognized research program as a cardiovascular epidemiologist with a particular focus on cardiovascular risk estimation across the lifespan. He has published more than 90 peer-reviewed original papers. He serves as an associate editor for Circulation. He also serves as one of the senior investigators in the Dallas Heart Study and one of the principal investigators of UT Southwestern’s Strategically Focused Research Network funded by the American Heart Association. Dr. Berry’s research has been funded by both the National Institutes of Health and the American Heart Association and his work has been recognized by numerous national awards. He is actively involved in leadership roles for the American Heart Association’s Council on Epidemiology and Prevention.
Bryan Taylor, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Jarett Berry, MD- has disclosed that he is a consultant for AstraZeneca and Roche; he also receives grant/research support from Abott, NIH, and Roche.
Javed Butler, MD, MPH, MBA–has disclosed that he is a consultant for Amgen, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CVRx, G3 Pharmaceutical, Innolife, Janssen, Luitpold, Medtronic, Merck, Novartis, Relypsa, and Vifor.
Muthiah Vaduganathan, MD, MPH–has disclosed that he is a consultant for Amgen, AstraZeneca, Baxter Healthcare, Bayer AG, Boehringer Ingelheim, and Relypsa and receives grant/research support from KL2/Catalyst Medical Research Investigator Training.
Kim Birtcher, MS, PharmD, AACC, FNLA, BCPS-AQ Cardiology, CDE, CLS–has no relevant financial relationships to disclose in relation to the content of this activity.
Debra K. Moser, PhD, RN, FAAN–has no relevant financial relationships to disclose in relation to the content of this activity.
Ambarish Pandey, MD, MSCS–has no relevant financial relationships to disclose in relation to the content of this activity.
Scott Urquhart, PA-C, DFAAPA–has disclosed that he is a consultant for AstraZeneca, Dexcom, Novo Nordisk. and Sanofi. He is a member of the speakers' bureau for AstraZeneca and Novo Nordisk.
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1 hour of Interprofessional Continuing Education (IPCE) credit for learning and change.
CEC designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This application-based activity is approved for 1.0 contact hour (.10 CEUs) of continuing pharmacy education credit (JA0007101-0000-20-008-L01-P).
This activity is designated for 1.0 contact hour.
Physician Assistants (AAPA)
Creative Educational Concepts has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Upon completion of a CE request form, statements of credit for physicians, physician assistants, and nurses will be issued within 30 business days. Pharmacy credit will be reported directly to the National Association of Boards of Pharmacy® NABP® CPE Monitor electronic CE tracking system.
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 ICPE
- 1.00 Participation